Biofrontera Inc. (BFRIW) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-19

Key Insights

Biofrontera Inc. reported its Q4 2025 and fiscal year 2025 financial results, indicating the company's financial and operational performance for the year.
The company's press release includes non-GAAP financial measures, which require reconciliation to the most directly comparable GAAP measures as per Regulation G.
Biofrontera Inc. is an emerging growth company, which means it may have elected to use the extended transition period for complying with new or revised financial accounting standards.

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-09

Biofrontera Inc. announced positive results from its Phase 2b study of Ameluz® PDT for the treatment of moderate to severe Acne Vulgaris, which could lead to the expansion of the company's product portfolio and future revenue growth.
The company's common stock and warrants are traded on the Nasdaq Stock Market, providing access to public capital markets and potential liquidity for investors.
As an emerging growth company, Biofrontera may benefit from certain regulatory and financial reporting exemptions, which could allow the company to focus resources on product development and commercialization.

Filed: 2026-02-26

Biofrontera Inc. received a favorable ruling from the Patent Trial and Appeal Board, which found the key Sun Patent held by Sun Pharmaceutical to be unpatentable.
The impact of this ruling on the ongoing legal proceedings between Biofrontera and Sun Pharmaceutical is still uncertain and will need to be monitored.
Biofrontera's ability to successfully defend its intellectual property rights could have significant implications for the company's long-term competitive position and financial performance.

Filed: 2026-02-09

Biofrontera Inc. announced positive results from its Phase 3 study of Ameluz® PDT for Actinic Keratoses, a key product in its pipeline.
The successful study results could lead to expanded regulatory approvals and commercialization opportunities for Ameluz®, potentially driving future revenue growth.
As an emerging growth company, Biofrontera's ability to advance its product candidates and achieve regulatory milestones will be crucial for investor sentiment.

Filed: 2026-01-13

Biofrontera Inc. issued a press release announcing preliminary unaudited revenues for Q4 and full year 2025, indicating the company's financial performance for the period.
The company's Q4 and full year 2025 results are still subject to completion of the review process and could materially differ from the preliminary estimates provided.
Biofrontera Inc. is an emerging growth company, which could impact its compliance with new or revised financial accounting standards.

Filed: 2026-01-07

Biofrontera Inc. received a notice from Nasdaq that its common stock price has fallen below the $1.00 per share minimum for continued listing, triggering a 180-day compliance period.
The company has until June 30, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
If the company fails to regain compliance within the 180-day period, it may be eligible for an additional 180-day compliance period by meeting other Nasdaq listing requirements, such as market value of publicly held shares.

Other reports for Biofrontera Inc.

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.